Guggenheim initiated coverage of GH Research (GHRS) with a Buy rating and $32 price target The firm’s thesis on GH is based around the belief that rapid-acting psychedelics like 5-MeO-DMT have the ...

It focuses on 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments. Its lead program, GH001 (inhalable mebufotenin), is in Phase 2 clinical trials for treatment-resistant depression ...

Fintel reports that on March 13, 2025, Guggenheim initiated coverage of GH Research (NasdaqGM:GHRS) with a Buy recommendation ...

GH Research PLC (NASDAQ:GHRS) is a biopharma company working on psychiatric and neurological disorders by developing novel and proprietary mebufotenin (5-MeO-DMT) therapies for conditions like ...

It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Receive News & Ratings for GH ...

GH Research PLC (NASDAQ:GHRS – Get Free Report) shares gapped up prior to trading on Friday . The stock had previously closed at $10.55, but opened at $10.99. GH Research shares last traded at $10.81, ...

or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.

GH001 – also known as mebufotenin – is an inhaled formulation of 5-MeO-DMT, based on a hallucinogenic substance secreted by a species of toad (Bufo alvarius) that has attracted a lot of ...

N-dimethyltryptamine (5-MeO-DMT) heading for phase 2 studies in depression and AUD in combination with psychotherapy. SUNHA candidate dropped There's also been some consolidation of Beckley's own ...